期刊
DRUG DISCOVERIES AND THERAPEUTICS
卷 10, 期 3, 页码 123-128出版社
INT RESEARCH & COOPERATION ASSOC BIO & SOCIO-SCIENCES ADVANCEMENT
DOI: 10.5582/ddt.2016.01041
关键词
Menaquinone; lysocin E; antibacterial agent
资金
- Genome Pharmaceutical Institute
- Tokyo Biochemical Research Foundation, TBRF
- MEXT KAKENHI [221S0002]
- Drug Discovery Support Promotion Project from Japan Agency for Medical Research and Development, AMED
- [26102714]
- [15H05783]
- Grants-in-Aid for Scientific Research [15H05783] Funding Source: KAKEN
The current trend of increasing infections by multidrug-resistant pathogens requires the discovery of novel antimicrobial agents with new target and selective toxicity towards pathogens. Menaquinone is a component of electron transport chains in a majority of anaerobic bacteria and Gram-positive bacteria. Due to its exclusivity in bacteria, menaquinone is thought to be a potential target for development of therapeutically effective antibacterial agents without side effects. In this review, we summarize inhibitors of menaquinone biosynthesis and antibiotics directly targeting menaquinone in bacteria.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据